Abstract:

Although collagen cross-linking (CXL) technology is still in the research and experimental stage in ophthalmology, but which is likely to significantly improve the mechanical strength of the collagen fibers, so a great number of ophthalmologists are becoming concerned about it. In recent years, based on the traditional CXL, the high-energy accelerated CXL, iontophoresis CXL and combination procedures are being described. Most of the experience gained from the treatment of the keratoconus. If individuals have been diagnosed as progressive keratoconus, they can be given CXL treatment early. After the operation, patients appear to increase the corneal stability and improve the visual acuity, while as to non-progression of keratoconus, the efficacy of the CXL is still in need of further study. In addition, CXL were attempted to be applied on the treatment of the iatrogenic keratoconus, transparent marginal degeneration, corneal edema and infectious corneal diseases, but the efficacy remains to be further verified.